What is the recommended management of gestational diabetes during pregnancy?

Management of Gestational Diabetes

Lifestyle modification with medical nutrition therapy and exercise is the first-line treatment for gestational diabetes, and if glycemic targets are not achieved, insulin should be added as the preferred pharmacologic agent. 1

Initial Management: Lifestyle Intervention

After GDM diagnosis, all women should begin with:

Medical Nutrition Therapy

• Work with a registered dietitian to develop an individualized meal plan
• Minimum 175 g carbohydrate daily (per Dietary Reference Intakes for pregnancy) 2
• Focus on carbohydrate type, amount, and distribution throughout the day to control postprandial glucose excursions 1
• For overweight/obese women: modest calorie restriction (33% reduction, approximately 1,600-1,800 kcal/day) can reduce blood glucose without causing ketonuria 3
• Avoid severe calorie restriction (<1,200 kcal/day) as this causes ketonemia and ketonuria 3
• Monitor for ketones if severe carbohydrate restriction is suspected 1

Physical Activity

• Regular aerobic exercise lowers fasting and postprandial glucose 3
• Minimum 3 episodes per week, each >15 minutes duration 3
• May require 2-4 weeks of regular exercise before glycemic improvement is seen 3

Glycemic Targets

Monitor capillary blood glucose with these targets 4, 5:

• Fasting: <95 mg/dL (5.3 mmol/L)
• 1-hour postprandial: <140 mg/dL (7.8 mmol/L) OR
• 2-hour postprandial: <120 mg/dL (6.7 mmol/L)

Approximately 70-85% of women can achieve control with lifestyle alone 5.

Pharmacologic Therapy: When Lifestyle Fails

Insulin - First-Line Agent

Insulin is the only FDA-approved medication for GDM and should be added when lifestyle modifications fail to achieve glycemic targets. 1, 2, 1

Why insulin is preferred:

• Does not cross the placenta to measurable extent 5
• Proven to improve perinatal outcomes in large randomized trials 1, 5
• Most safety data available 1

Both multiple daily injections and continuous subcutaneous insulin infusion are acceptable delivery methods 1.

Oral Agents - NOT First-Line

Critical caveat: Metformin and glyburide should NOT be used as first-line agents 1, 2, 1 because:

Metformin Concerns:

• Crosses the placenta readily, with umbilical cord levels equal to or higher than maternal levels 1
• Long-term offspring data show concerning metabolic effects: 9-year-old children exposed to metformin had higher BMI, increased waist-to-height ratio, and greater waist circumference compared to insulin-exposed children 1
• Meta-analysis shows metformin exposure results in smaller neonates with accelerated postnatal growth and higher childhood BMI 1
• Fails to provide adequate glycemic control in 25-28% of women with GDM 1, 5
• Contraindicated in women with hypertension, preeclampsia, or risk for intrauterine growth restriction due to potential for growth restriction or acidosis with placental insufficiency 1

Glyburide (Sulfonylurea) Concerns:

• Crosses the placenta (umbilical cord levels 50-70% of maternal) 1
• Associated with higher rates of neonatal hypoglycemia, macrosomia, and increased neonatal abdominal circumference compared to insulin 1, 5
• Failed to achieve adequate control in 23% of women 1, 5
• No long-term safety data for offspring available 1

When Oral Agents May Be Considered:

Only after discussing known risks and lack of long-term safety data, oral agents may be alternatives for women who cannot use insulin safely or effectively due to cost, language barriers, comprehension, or cultural influences 1. However, this is a compromise position, not the standard of care.

Monitoring and Follow-up

• Self-monitoring of blood glucose: Fasting and postprandial testing recommended 2, 5
• A1C monitoring: Target <6% if achievable without hypoglycemia, but A1C is secondary to self-monitoring due to altered red blood cell kinetics in pregnancy 4, 6
• Continuous glucose monitoring (CGM): Insufficient data to support routine use in GDM (unlike type 1 diabetes in pregnancy) 1
• Telehealth visits: Improve outcomes compared to standard in-person care 1

Special Considerations

Metformin for PCOS: If metformin was used for ovulation induction in polycystic ovary syndrome, it should be discontinued by the end of the first trimester 2, 1, 6.

Weight gain targets: Follow 2009 Institute of Medicine recommendations based on pre-pregnancy BMI 2.

Postpartum: Women with GDM should undergo 75-g oral glucose tolerance test at 4-12 weeks postpartum using non-pregnancy criteria to screen for persistent diabetes or prediabetes 6.